Nemysis Limited Announces the Grant of Further IP for its IHAT Oral Iron Supplement

Nemysis Limited has announced a significant enhancement of its intellectual property (IP) portfolio concerning its nanoparticulate oral iron supplement, IHAT (Iron Hydroxide Adipate Tartrate). This development reinforces the supplement's positioning for safe treatment of iron deficiency and iron deficiency anaemia.

Recently, a new patent (WO2021204705) was granted in Europe for the use of IHAT in treating and preventing iron deficiency in liver disease. Experimental and toxicological evidence supports that IHAT does not cause iron overload in the liver. This new addition augments the existing global patent protections covering various therapeutic uses and manufacturing processes of IHAT.

Dr. Cristina Comelli, Chief Scientific Officer, emphasized the unique application of IHAT in treating anaemia and liver diseases. Dr. Nuno Faria, Chief Technical Officer, added that this patent, together with existing protections, ensures robust global protection for IHAT, now commercialized in multiple markets.